Lack of indication for use of antiparkinson medication. A follow-up study.
D000293:Adolescent; D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008607:Intellectual Disability / Q000188:drug therapy; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D008875:Middle Aged; D009662:Nortropanes / Q000627:therapeutic use; D010276:Parasympatholytics / Q000008:administration & dosage / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000517:prevention & control; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D011352:Procyclidine / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy; D013375:Substance Withdrawal Syndrome; D013451:Sulfonic Acids / Q000627:therapeutic use; D013997:Time Factors; D014149:Tranquilizing Agents / Q000009:adverse effects* / Q000627:therapeutic use; D014282:Trihexyphenidyl / Q000627:therapeutic use
D009662:Nortropanes; D010276:Parasympatholytics; D013451:Sulfonic Acids; D014149:Tranquilizing Agents; D014282:Trihexyphenidyl; D011352:Procyclidine